These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22422808)

  • 1. Time-patterns of annualized relapse rates in randomized placebo-controlled clinical trials in relapsing multiple sclerosis: a systematic review and meta-analysis.
    Nicholas R; Straube S; Schmidli H; Pfeiffer S; Friede T
    Mult Scler; 2012 Sep; 18(9):1290-6. PubMed ID: 22422808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Explaining temporal trends in annualised relapse rates in placebo groups of randomised controlled trials in relapsing multiple sclerosis: systematic review and meta-regression.
    Steinvorth SM; Röver C; Schneider S; Nicholas R; Straube S; Friede T
    Mult Scler; 2013 Oct; 19(12):1580-6. PubMed ID: 23471144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: Model-Based Meta-Analyses for Confirmed Disability Accumulation and Annualized Relapse Rate.
    Hennessy B; Zierhut ML; Kracker H; Keenan A; Sidorenko T
    Mult Scler Relat Disord; 2022 Aug; 64():103908. PubMed ID: 35803162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design.
    Nicholas R; Straube S; Schmidli H; Schneider S; Friede T
    Mult Scler; 2011 Oct; 17(10):1211-7. PubMed ID: 21586489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis.
    Newsome SD; Kieseier BC; Arnold DL; Shang S; Liu S; Hung S; Sabatella G
    J Neurol; 2016 Sep; 263(9):1778-87. PubMed ID: 27314959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
    Roskell NS; Zimovetz EA; Rycroft CE; Eckert BJ; Tyas DA
    Curr Med Res Opin; 2012 May; 28(5):767-80. PubMed ID: 22462530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changing EDSS Progression in Placebo Cohorts in Relapsing MS: A Systematic Review and Meta-Regression.
    Röver C; Nicholas R; Straube S; Friede T
    PLoS One; 2015; 10(9):e0137052. PubMed ID: 26327532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data.
    Stellmann JP; Neuhaus A; Herich L; Schippling S; Roeckel M; Daumer M; Martin R; Heesen C
    PLoS One; 2012; 7(11):e50347. PubMed ID: 23209717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing changes in relapse rates in multiple sclerosis.
    Inusah S; Sormani MP; Cofield SS; Aban IB; Musani SK; Srinivasasainagendra V; Cutter GR
    Mult Scler; 2010 Dec; 16(12):1414-21. PubMed ID: 20810517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.
    Miller AE; O'Connor P; Wolinsky JS; Confavreux C; Kappos L; Olsson TP; Truffinet P; Wang L; D'Castro L; Comi G; Freedman MS;
    Mult Scler; 2012 Nov; 18(11):1625-32. PubMed ID: 22723573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of long-term interferon discontinuation in newly diagnosed relapsing multiple sclerosis.
    Moccia M; Palladino R; Carotenuto A; Russo CV; Triassi M; Lanzillo R; Brescia Morra V
    Mult Scler Relat Disord; 2016 Nov; 10():90-96. PubMed ID: 27919507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to first relapse as an endpoint in multiple sclerosis clinical trials.
    Sormani MP; Signori A; Siri P; De Stefano N
    Mult Scler; 2013 Apr; 19(4):466-74. PubMed ID: 22914849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.
    Martinelli Boneschi F; Rovaris M; Johnson KP; Miller A; Wolinsky JS; Ladkani D; Shifroni G; Comi G; Filippi M
    Mult Scler; 2003 Aug; 9(4):349-55. PubMed ID: 12926839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis.
    McCool R; Wilson K; Arber M; Fleetwood K; Toupin S; Thom H; Bennett I; Edwards S
    Mult Scler Relat Disord; 2019 Apr; 29():55-61. PubMed ID: 30677733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree.
    Cutter GR; Knappertz V; Sasson N; Ladkani D
    BMC Neurol; 2016 Sep; 16():176. PubMed ID: 27639853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
    Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Confavreux C; O'Connor P; Comi G; Freedman MS; Miller AE; Olsson TP; Wolinsky JS; Bagulho T; Delhay JL; Dukovic D; Truffinet P; Kappos L;
    Lancet Neurol; 2014 Mar; 13(3):247-56. PubMed ID: 24461574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.